DMII
Drugs Made In America Acquisition II Corp. Ordinary SharesKey Statistics
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on identifying and merging with innovative players in the pharmaceuticals and biotechnology sectors, prioritizing advancements in domestic drug manufacturing. Leveraging a seasoned management team with considerable industry expertise, DMII aims to execute strategic transactions that respond to market dynamics and foster sustainable practices. The company's mission encompasses enhancing supply chain resilience and promoting U.S. healthcare self-sufficiency, ultimately driving long-term value creation for shareholders and contributing to the growth of the American pharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -812,113 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.32% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.28 |
| Price-to-Book | 1.31 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $63.70M |
| Float | $50.26M |
| % Insiders | 15.21% |
| % Institutions | 70.44% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DMII and any ticker you trade — then tracks every position and per-strategy win rate.